Biologics Contract Development Market Overview, Analysis And Demand By 2034
Focused on real-world business use, this report highlights what’s changing in the biologics contract development market and what companies should prepare for next.
What Is The Current Outlook For The Biologics Contract Development Market By 2025?
The biologics contract development market size has grown rapidly in recent years. It will grow from $7.75 billion in 2024 to $8.55 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to biologics market growth, rise in biopharmaceuticals, complexity of biologics, patent expirations, cost efficiency.
The biologics contract development market size is expected to see rapid growth in the next few years. It will grow to $13.08 billion in 2029 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to digitalization and data analytics, risk management, flexibility and scalability, burgeoning investment in r&d, precision medicine and personalized therapies. Major trends in the forecast period include regenerative medicine, risk mitigation strategies, global collaborations, advanced technologies, technological integration.
Get your free sample today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8219&type=smp
What Are The Key Driving Factors For The Growth Of The Biologics Contract Development Market?
The rising prevalence of chronic diseases is expected to propel the biologics contract development market going forward. Chronic diseases refer to an illness that lasts for a year or longer that requires ongoing medical attention. The rise in chronic disease cases is increasing the demand for developing novel drugs, including biologics, thereby promoting the biologics contract development market. For instance, in September 2024, according to the reports published by the Office for Health Improvement & Disparities, a UK-based government, in the first half of 2023, there were 3,940 excess deaths attributed to chronic lower respiratory diseases, marking a 30% increase compared to expected rates. For the entire year, this number rose to 5,363, reflecting a 22% increase overall. Therefore, the rising prevalence of chronic diseases will drive the growth of the biologics contract development market.
Global Biologics Contract Development Market Report Segmentation
The biologics contract developmentmarket covered in this report is segmented –
1) By Source: Microbial; Mammalian; Others Sources
2) By Indication: Oncology; Immunological Disorders; Cardiovascular Disorders; Hematological Disorders; Others Indications
3) By Product Service: Cell Line Development; Process Development; Others Product Services
Subsegments:
1) By Microbial: Bacterial Sources; Yeast Sources; Fungal Sources
2) By Mammalian: Chinese Hamster Ovary (CHO) Cells; Human Embryonic Kidney (HEK) Cells; Hybridoma Cells
3) By Other Sources: Plant-Based Systems; Insect Cell Systems; Algal Sources
What Are The Key Trends And Market Opportunities In The Biologics Contract Development Sector?
Technological advancements are gaining popularity in the biologics contract development market. Major companies in the biologics contract development market are integrating advanced technologies to sustain their position in the market. For instance, in January 2022, Lonza, a Switzerland-based contract manufacturing and development solutions company, launched bYlok technology platform to design and manufacture bispecific antibodies. It helps to solve the light-heavy chain mispairing issue with high yields, >95% accuracy, and the ability to maintain a mAb-like format. It can be accessed by pharma and biotech companies through a simple research license.
Who Are The Leading Players In The Biologics Contract Development Market?
Major companies operating in the biologics contract development market are WuXi Biologics, Abzena Ltd., Fujifilm Diosynth Biotechnologies, KBI Biopharma, AGC Biologics, Thermo Fisher Scientific Inc, LakePharma Inc., GenScript Biotech Corporation, Bionova Scientific Inc., Boehringer Ingelheim GmbH, STC Biologics, Siegfried Evionnaz SA, BioAgilytix Labs Inc., Samsung BioLogics, Forge Biologics, Lonza Group, Catalent Inc., AbbVie Inc., Cytovance Biologics, Emergent BioSolutions, Eurofins CDMO, Meridian Life Science Inc., Merck Group, Patheon N.V., ProBioGen AG, Rentschler Biopharma SE, Sartorius AG, Syngene International Limited, Vibalogics GmbH, Yposkesi
View the full biologics contract development market report here:
https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report
Which Region Is Projected To Hold The Largest Market Share In The Global Biologics Contract Development Market By 2029?
North America was the largest region in the biologics contract development market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics contract development market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment